Magnetic Brain Stimulation for Depression: Expanding Access in Quebec
A recent scientific opinion suggests that magnetic brain stimulation therapy should be more widely available to adults in Quebec who haven’t responded to conventional depression treatments. While approved by Health Canada since 2002, access to this therapy remains uneven across the province, raising concerns about equitable healthcare.
Understanding Treatment-Resistant Depression
Approximately 30% of individuals with depression do not experience relief from standard treatments like psychotherapy and antidepressants. This is known as treatment-resistant depression . Repeated transcranial magnetic stimulation (rTMS) offers a potential alternative for these patients.
How rTMS Works
rTMS involves applying a coil to the scalp to deliver brief magnetic pulses to specific brain regions. These pulses modulate activity in areas that regulate emotions, which are often disrupted in individuals with depression. The treatment is non-invasive, doesn’t require anesthesia, and generally has few side effects .
Current Access in Quebec
Despite being covered by the Quebec public health plan since 2013, access to rTMS is not uniform. As of recently, only 7 out of 16 health regions in Quebec have rTMS devices available in the public network. This disparity leads to unequal access to care, with some patients facing significant barriers to treatment .
INEES Recommendation and Cost Considerations
The National Institute of Excellence in Health and Social Services (INESSS) concluded in January that rTMS is effective for treatment-resistant depression, well-tolerated, and has limited side effects. They recommend offering it to adults who haven’t responded to initial treatments. However, the cost of an rTMS device is approximately $110,000, excluding personnel costs . Santé Québec acknowledges financial constraints, human resources, and institutional autonomy as factors contributing to the access gap.
Benefits and Efficacy of rTMS
rTMS may offer a faster intervention compared to other treatments for resistant depression and doesn’t require anesthesia or an operating room. While not effective for everyone, studies show that, on average, about half of those receiving rTMS experience significant improvements, and roughly a third achieve remission from depression . For those who respond, the therapy can often be effective if repeated in the future.
The Role of CanStim
The Canadian Platform for Trials in Non-Invasive Brain Stimulation (CanStim) is a national platform dedicated to advancing research in non-invasive brain stimulation, including rTMS, for stroke recovery and other neurological conditions. CanStim aims to optimize rTMS protocols and bridge the gap between research and clinical practice .
Looking Ahead
Santé Québec is currently reviewing the INESSS recommendations to determine how to expand access to rTMS therapy. Addressing the inequities in access and investing in infrastructure and training are crucial steps to ensure that more Quebecers can benefit from this potentially life-changing treatment.